For healthcare professionals only


Dornase alfa for cystic fibrosis

BMJ 1995; 310 doi: (Published 10 June 1995) Cite this as: BMJ 1995;310:1533

Patients should not be denied a safe, effective treatment

  1. Andrew Bush,
  2. Duncan M Geddes,
  3. Margaret E Hodson,
  4. Mark Rosenthal,
  5. Robert Dinwiddie,
  6. Colin Wallis,
  7. David E Stableforth,
  8. Steven P Conway,
  9. James M Littlewood
  1. Consultant paediatrician Consultant physician Consultant physician Consultant paediatrician Royal Brompton Hospital, London SW3 6NP
  2. Consultant paediatrician Consultant paediatrician Hospital for Sick Children, Great Ormond Street, London
  3. Consultant physician Heartlands Hospital, Birmingham
  4. Consultant physician and paediatrician Seacroft Hospital, Leeds
  5. Consultant paediatrician St James's University Hospital, Leeds

    EDITOR,—We were interested to read a paper in the Drug and Therapeutics Bulletin on dornase alfa,1 and as the clinicians in the United Kingdom with the most experience with dornase alfa we must profoundly disagree with the paper's conclusions that, on the evidence available, dornase alfa should not be added to the formulary. The trouble with any unsigned recommendation is that readers do not know how many clinicians with experience of cystic fibrosis, treatment with dornase alfa, or both, were responsible for the final draft. Similarly they cannot judge whether considerations of cost were paramount.

    We have seen many patients improve considerably with this treatment, and in many cases there has been an improvement of …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription